Ulrika Stierner

University of Gothenburg — Sweden

Medicine · Health Sciences

38h-index4.0kcitations104works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cutaneous Melanoma Detection and Management(21), Testicular diseases and treatments(19), Immunotherapy and Immune Responses(17), Renal cell carcinoma treatment(13), Cancer Genomics and Diagnostics(11)

Publications104 total

Plasma and Urine Free Glycosaminoglycans as Monitoring and Predictive Biomarkers in Metastatic Renal Cell Carcinoma: A Prospective Cohort Study
JCO Precision Oncology·2023· 8 citedOpen Access
Noninvasive detection of any-stage cancer using free glycosaminoglycans
Proceedings of the National Academy of Sciences·2022· 59 citedOpen Access
Plasma and Urine Free Glycosaminoglycans as Monitoring Biomarkers in Nonmetastatic Renal Cell Carcinoma—A Prospective Cohort Study
European Urology Open Science·2022· 14 citedOpen Access
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
Nature Communications·2021· 170 citedOpen Access
Urine free glycosaminoglycans as monitoring biomarkers in confined renal cell carcinoma - A prospective observational study
European Urology·2021
Detection of any-stage cancer using plasma and urine glycosaminoglycans.
Journal of Clinical Oncology·2021· 5 cited
Plasma and urine free glycosaminoglycans as monitoring and predictive biomarkers in metastatic renal cell carcinoma: A prospective observational study.
Journal of Clinical Oncology·2021· 1 cited
Glycosaminoglycan profiling in patients’ plasma and urine predicts the occurrence of metastatic clear cell renal cell carcinoma
Cell Reports·2021· 1 citedOpen Access
Molecular profiling of driver events in metastatic uveal melanoma
Nature Communications·2020· 162 citedOpen Access
Correction: A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma
Cell Death and Disease·2020· 2 citedOpen Access
Phase II multicenter open label study of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study)
Annals of Oncology·2019· 10 citedOpen Access
Molecular profiling of driver events and tumor-infiltrating lymphocytes in metastatic uveal melanoma
2019· 1 cited
Real-world data on PD-1 inhibitor therapy in metastatic melanoma
Acta Oncologica·2019· 42 citedOpen Access
Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study
BMC Cancer·2019· 70 citedOpen Access
Real-world data on PD-1 inhibitor therapy in metastatic melanoma
Figshare·2019Open Access
A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma
Cell Death and Disease·2018· 42 citedOpen Access
Erratum: BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
Cell Death and Disease·2017Open Access
BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
Cell Death and Disease·2017· 19 citedOpen Access
An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Nature Medicine·2017· 173 citedOpen Access
The ABC-study: A randomized phase III study comparing one course of adjuvant bleomycin, etoposide, and cisplatin (BEP) and one course of carboplatin AUC7 in clinical stage I seminomatous testicular cancer.
Journal of Clinical Oncology·2017· 4 cited
page 1 of 6Next →

Frequent Co-authors

Johan Hansson(11), Eva Cavallin‐Ståhl(10), Jonas A. Nilsson(8), Lars Ny(8), Gabriella Cohn‐Cedermark(7), Roger Olofsson Bagge(7), Inger Rosdahl(7), A Augustsson(7), Christian Ingvar(7), Torgrim Tandstad(6), Olbjørn Klepp(6), Henrik Jespersen(6), Lisa M. Nilsson(6), Peter Naredi(6), Carl W. Langberg(5), Roy M. Bremnes(5), M Suurküla(5), Olav Dahl(4), Anna Laurell(4), Max Levin(4)